Chemotherapy for breast cancer that has spread to the spinal fluid
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a chemotherapy drug given directly into the spinal fluid for people with HER2-negative breast cancer that has spread to the lining of the brain and spinal cord (called leptomeningeal metastasis). It may help when standard treatments have stopped working or caused too many side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have HER2-negative breast cancer that has spread to the lining of the brain or spinal cord
- Standard treatments have failed or caused side effects that are too hard to handle
- Be well enough to carry out daily activities with some help (ECOG score 3 or less)
- Have acceptable blood counts, liver and kidney function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.
This trial tests a drug called pemetrexed, given directly into the fluid around the spinal cord (intrathecal), for people with lung cancer that has spread to the brain and spinal cord lining and is no longer controlled by the targeted therapy osimertinib.
This trial tests a combination treatment for cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis). It uses an antibody given directly into the spinal fluid along with a chemotherapy drug, with the goal of targeting the cancer more effectively.
This Phase 2 trial tests giving pemetrexed directly into the spinal fluid to treat cancer that has spread to the brain’s and spinal cord’s lining (leptomeningeal metastasis). It is for people with EGFR-mutant non-squamous lung cancer whose disease progressed after osimertinib, and who may benefit from a targeted treatment delivered to the area affected in the brain lining.
This study tests whether giving a higher dose of an EGFR-targeted pill, either alone or with a chemotherapy drug injected into the fluid around the spinal cord, can control lung cancer that has spread to the lining of the brain (called leptomeningeal metastases). It is for people whose cancer has gotten worse in the brain lining while on a standard dose of this type of medication.
This trial tests a radioactive nanoparticle drug given directly into the fluid around the brain and spine to treat cancer that has spread to the lining of the brain or spinal cord (leptomeningeal metastases). It aims to see if this targeted treatment is safe and might help shrink or control the cancer.
Hear when a new HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.